OCTOBER MONTH IN REVIEW: BIGGEST NEWS & EVENTS

October has been a huge month for the kratom industry, particularly the battle between natural botanical kratom and concentrated or chemically manipulated 7-OH products.

1. Federal government draws a new line between natural kratom and concentrated 7-OH                                                                                

    October 9–14, 2026

The DEA, Department of Justice, and HHS announced a revised approach to regulating 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI).

Instead of treating every detectable amount of these compounds alike, the federal proposal would use specific concentration and alkaloid-ratio thresholds.

Key proposed thresholds include:

• More than 1 mg/g of 7-OH, MGPI, or their combined amount in solid products.

• More than 1 mg/mL in liquid products.

• A mitragynine-to-7-OH/MGPI ratio below 100:1.

Exceeding either applicable threshold could bring a product within the proposed Schedule I controls.

Why this is huge: Federal regulators explicitly acknowledged that trace quantities of certain alkaloids can occur in botanical kratom, while attempting to target intentionally enhanced products.

This is an important distinction for manufacturers focused on botanical formulations. However, these were updated scheduling notices, not a blanket declaration that all natural kratom products are FDA-approved or federally authorized.

2. American Kratom Association celebrates a major legal breakthrough

October 9, 2026

The American Kratom Association announced a resolution of its litigation challenging unintended consequences of federal scheduling rules affecting mitragynine pseudoindoxyl.

The AKA welcomed the government's new threshold approach as an important step toward protecting natural kratom from being caught up in enforcement intended for chemically manipulated opioid products.

Why it's juicy: This represents a potentially important victory for the natural-kratom industry's advocacy efforts, while leaving substantial federal regulatory questions unresolved.

ETHA podcast headline: Did the Kratom Industry Just Win Its Biggest Federal Battle of 2026?

3. Two University of Mississippi student deaths ignite a national kratom controversy

October 1–14, 2026

The deaths of two University of Mississippi students sparked extensive headlines, political calls for additional restrictions, and debate about whether concentrated kratom-related compounds should be distinguished from natural kratom.

The most important development: Lafayette County investigators clarified that their initial warning did not establish that kratom or any specific substance caused either death. Autopsy and toxicology findings were still needed.

Meanwhile, the American Kratom Association urged Mississippi's attorney general to withdraw support for a blanket kratom ban and instead target dangerous chemically manipulated products.

Why it's juicy: A developing tragedy has become a national fight about public safety, responsible reporting, and the potential consequences of banning an entire botanical category.

ETHA podcast headline: Two Tragic Deaths, a National Kratom Scare, and the Facts Still Missing.

4. Three U.S. senators push for scheduling the entire kratom plant

October 7, 2026

Senators Chuck Grassley, Mike Lee, and Susan Collins called on federal officials to accelerate the scheduling of 7-OH and consider permanent Schedule I controls covering the kratom plant and its derivatives.

This goes substantially further than simply controlling chemically manipulated 7-OH products.

Why it's juicy: While regulators are developing thresholds to distinguish natural kratom from concentrated derivatives, influential senators are advocating for much broader federal restrictions.

That creates a direct political clash over the industry's future.

ETHA podcast headline: Washington Wants to Ban the Whole Kratom Plant? Three Senators Make Their Move.

5. Michigan considers banning kratom as poison-control cases rise

October 13, 2026

Michigan legislators are considering competing approaches: prohibiting kratom outright or regulating it through labeling, consumer safeguards, and restrictions on concentrated derivatives.

Michigan's poison-control center recorded 87 kratom-related incidents in 2025, an 81% increase from 2024, according to Axios. Those figures do not independently establish which formulations caused each incident.

Why it's juicy: Michigan could become another major battleground over natural kratom access, especially as lawmakers respond to national headlines.

ETHA podcast headline: Another State Wants to Ban Kratom — But Are Lawmakers Targeting the Right Products?

6. Rutgers researcher warns that sweeping restrictions could hurt promising medical research

October 8, 2026

Researchers at Rutgers University raised concerns about how Schedule I controls on powerful kratom-related compounds might complicate scientific research.

Rutgers researcher Jenny Wilkerson discussed the tension between protecting the public from dangerous opioid-like substances and ensuring scientists can investigate potentially valuable compounds.

This adds an important scientific perspective to the regulatory controversy.

Why it's juicy: The debate is no longer just about smoke shops and consumer products. It also involves the future of pharmaceutical research.